stoxline Quote Chart Rank Option Currency Glossary
  
PureTech Health plc (PRTC)
28.5001  -0.34 (-1.18%)    03-28 16:00
Open: 28.66
High: 28.66
Volume: 5,054
  
Pre. Close: 28.84
Low: 28.36
Market Cap: 770(M)
Technical analysis
2024-03-28 4:53:42 PM
Short term     
Mid term     
Targets 6-month :  34.33 1-year :  40.1
Resists First :  29.39 Second :  34.33
Pivot price 27.08
Supports First :  26.37 Second :  24.5
MAs MA(5) :  28.57 MA(20) :  26.66
MA(100) :  23.5 MA(250) :  25.14
MACD MACD :  1 Signal :  0.7
%K %D K(14,3) :  87.3 D(3) :  89.9
RSI RSI(14): 60.2
52-week High :  31.36 Low :  17.07
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
[ PRTC ] has closed below upper band by 25.1%. Bollinger Bands are 1% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 28.69 - 28.85 28.85 - 28.98
Low: 27.97 - 28.17 28.17 - 28.34
Close: 28.2 - 28.5 28.5 - 28.76
Company Description

PureTech Health plc, a clinical-stage biotherapeutics company, discovers, develops, and commercializes medicines for inflammatory, fibrotic and immunological, intractable cancers, lymphatic and gastrointestinal, neurological and neuropsychological, and other diseases in the United States. The company offers KarXT targeting muscarinic acetylcholine receptors to treat schizophrenia and psychosis in Alzheimer's disease; a regenerative biology platform for androgenetic alopecia, epithelial ageing, and other medical conditions; an immunomodulation platform to treat chronic and acute inflammatory disorders; oral therapies based on defined consortia of bacteria is isolated from the human microbiome; and therapies to treat cognitive dysfunction associated with depression, multiple sclerosis, post COVID and ICU, and cancer related conditions. It also provides hematopoietic stem cell based therapies for patients with blood cancer; a voice-based technology platform to detect voice changes linked to health conditions; and a technology platform for the oral delivery of biologics, vaccines, and other drugs. In addition, the company is developing LYT-100 to treat lymphedema, and other lymphatic flow disorders; LYT-200, a IgG4 monoclonal antibody to target galectin-9; LYT-210 to treat solid tumors; Glyph, a synthetic lymphatic targeting chemistry platform; Orasome technology to enable the oral administration of macromolecule therapeutic payloads; meningeal lymphatics platform to treat Alzheimer's and Parkinson's diseases; and Alivio technology platform for inflammation-targeted disease immunomodulation. PureTech Health plc has collaboration and license agreements with Boehringer Ingelheim International GMBH; Eli Lilly and Company; Imbrium Therapeutics L.P.; and Shionogi & Co., Ltd. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.

Headline News

Wed, 27 Mar 2024
PureTech Health (NASDAQ:PRTC) Shares Gap Down to $29.40 - MarketBeat

Wed, 27 Mar 2024
PureTech Health (NASDAQ:PRTC) Shares Gap Up to $27.54 - Defense World

Sat, 23 Mar 2024
PureTech Health Stock: Repeat What Works (NASDAQ:PRTC) - Seeking Alpha

Thu, 21 Mar 2024
PureTech Health (NASDAQ:PRTC) Shares Gap Up to $25.85 - Defense World

Tue, 19 Mar 2024
PureTech Health Announces $100 Million Shareholder Return - TipRanks.com - TipRanks

Tue, 19 Mar 2024
PureTech Health (NASDAQ:PRTC) Shares Gap Up to $25.85 - MarketBeat

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Outperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Neutral
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Neutral
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Neutral
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 0 (M)
Shares Float 27 (M)
Held by Insiders 1.5473e+008 (%)
Held by Institutions 0 (%)
Shares Short 1 (K)
Shares Short P.Month 0 (K)
Stock Financials
EPS -1.6816e+008
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin 0 %
Operating Margin -2 %
Return on Assets (ttm) 417.8 %
Return on Equity (ttm) -14.3 %
Qtrly Rev. Growth 1.174e+007 %
Gross Profit (p.s.) -58.73
Sales Per Share -7.69
EBITDA (p.s.) 0
Qtrly Earnings Growth -1.8 %
Operating Cash Flow 0 (M)
Levered Free Cash Flow -157 (M)
Stock Valuations
PE Ratio -0.01
PEG Ratio 0
Price to Book value 0
Price to Sales -3.72
Price to Cash Flow 14.4
Stock Dividends
Dividend 0
Forward Dividend 4320
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android